Cat. No. 3768
Alternative Name: SU 11248
Chemical Name: N-[2-(Diethylamino)ethyl]-5-[(Z)-(5
Biological ActivityPotent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Mendel et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin.Cancer Res. 9 327. PMID: 12538485.
O'Farrell et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 3597. PMID: 12531805.
Faivre et al (2007) Molecular basis for sunitinib efficacy and future clinical development Nat.Rev.Drug Discov. 6 734. PMID: 17690708.
Roskoski (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem.Biophys.Res.Comm. 356 323.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Sunitinib malate, supplier, Potent, VEGFR, PDGRb, PDGFRbeta, PDGFRβ, FGFR, inhibitors, Vascular, Endothelial, Growth, Factor, Receptors, KDR, Flt, Flk, Kit, Receptor, Tyrosine, Kinases, RTKs, Fibroblast, platelet, derived, CD117, SU11248, Pfizer
Find multiple products by catalog number
New Products in this Area
EphA4 receptor tyrosine kinase antagonist; neuroprotectivePD 90780
Inhibits NGF binding to p75NTRLM11A 31 dihydrochloride
Nonpeptide p75NTR ligand; neuroprotectiveToceranib
Potent PDGFR and VEGFR inhibitorNVP ADW 742
ATP-competitive inhibitor of IGF1RKRCA 0008
Potent Ack1 and ALK dual inhibitor; orally bioavailableDDR1-IN-1 dihydrochloride
Selective DDR1 inhibitor
November 15 - 19, 2014
Washington D.C., USA